X-linked hyper-IgM syndrome (XHIM) caused by CD40L mutations is a primary immunodeficiency condition that increases susceptibility to opportunistic infections. Disseminated cryptococcosis in XHIM is rarely reported in children. Here, we report two related boys who have a novel hemizygous frameshift c.208delC mutation of CD40L. They live in the western region of Thailand and developed disseminated cryptococcosis while receiving regular intravenous immunoglobulin supplementation.
Introduction
X-linked hyper-IgM syndrome (XHIM; OMIM 308230) is a rare primary immunodeficiency disorder, but it is the most common type of hyper-IgM syndrome (HIGM). XHIM is caused by mutations of the CD40 ligand (CD40L; OMIM 300386), which is located at Xq26.3-27.1. 1 To date, more than 130 mutations have been identified throughout the CD40L. 2 As a result of the class-switching defect and T-cell dysfunction, patients are susceptible to opportunistic infections (OI), including Pneumocystis jirovecii pneumonia (PJP), Cryptosporidium infection, and infections by members of the herpesvirus family. 3 Cryptococcus neoformans is a common OI that is mostly found in patients with cell-mediated immunodeficiency, but it is rarely reported in patients with XHIM.
Here, we report two male cousins with a novel mutation of the CD40L that developed disseminated cryptococcosis while receiving regular intravenous immunoglobulin (IVIG) supplementation.
CD19 516 cells/mm 3 (14.15%). Lymphocyte proliferation in response to phytohemagglutinin (PHA) was normal.
Patient B, a younger cousin of patient A (Figure 1 Since the diagnosis of XHIM, based on the clinical presentations and immunological findings, both patients have been receiving monthly IVIG supplementation and daily trimethoprim-sulfamethoxazole for PJP prophylaxis. IgG trough levels have been consistently above 600 mg/dL in both patients.
Mutation analysis of the CD40L gene
After written informed consent was obtained, molecular analysis of the CD40L was performed for the probands and their mothers in 2014. Briefly, genomic DNA was extracted from peripheral blood lymphocytes using commercially available kits according to manufacturer's instructions. Five coding exons and exon/intron junctions of CD40L were separately amplified by polymerase chain reaction (PCR) using previously described 3 , protein 89 mg/dl, and sugar < 4.32 mg/dl. Encapsulated budding yeasts were identified by direct examination with India ink. The cryptococcal antigen titer was > 1:1,024 in both CSF and serum. Blood and CSF cultures both grew Cryptococcus neoformans. The patient received combination intravenous amphotericin B (1 mg/kg/day) and oral fluconazole (12 mg/kg/day) treatment. At 4 weeks of treatment, rare encapsulated yeasts were found in the CSF. Amphotericin B was discontinued, but fluconazole was continued for 6 additional weeks for a total of 10 weeks. When that treatment regimen was completed, oral fluconazole was decreased to a maintenance dose of 6 mg/kg/day for prophylaxis against recurrence. One week after the start of prophylactic treatment, our patient developed primers. 4 The results revealed a novel hemizygous deletion of cytosine at nucleotide position 208 or c.208delC mutation in exon 2 of CD40L ( Figure 1A) . This frameshift mutation resulted in a premature termination codon at position 83 (p.Glu70Argfs *13). Molecular analysis of maternal DNA revealed heterozygosity of the same mutation ( Figure 1B) , which indicates that this mutation was inherited from his mother. The genetic testing of the mother and other available family members was performed. Other affected males and carrier females were identified ( Figure  2) . The reference sequences were NM_000074 and NP_000065 for CD40L cDNA and amino acid positions, respectively.
Report of case

Disseminated cryptococcal infection
At 12 years of age, patient A presented with fever and severe headache. Physical examination revealed signs of meningeal irritation. Laboratory investigations revealed white blood cell Figure 2 . Pedigree of the proband's family.
Cryptococcosis in a novel CD40L defect
Discussion
We report 2 boys cousins that harbor a novel mutation of the CD40L, and both have been regularly treated with monthly IVIG and daily trimethoprim-sulfamethoxazole prophylaxis since XHIM diagnosis. In spite of our efforts to avert OI in these two patients, both developed disseminated cryptococcosis within 2 months of each other.
Mutations in the CD40L are highly heterogenous, Missense mutations and small deletions are the main types, accounting for 50-70% of mutations. [5] [6] [7] [8] [9] We identified a novel hemizygous cytosine deletion at nucleotide position 208 (c.208delC) in exon 2 of the CD40L in our patients. This mutation is predicted to result in premature termination at codon 83 (p.Glu70Argfs*13), which causes truncation of a portion of the extracellular unique (ECU) domain and the entire extracellular C-terminal TNF homology (TNFH) domain, both of which play an important role in the function of CD40L. Based on our review of the literature, this frameshift mutation has never been reported.
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Cryptococcus neoformans is an encapsulated yeast that is predominantly isolated from pigeon droppings, and from soil contaminated with avian excreta. It causes life-threatening meningoencephalitis mainly in patients with cell-mediated immune deficiency, such as human immune deficiency virus (HIV) infection. 10 However, it has only rarely been reported in patients with XHIM.
Many factors predispose patients to cryptococcal infection, including host immunologic defect and environmental factors. Although disseminated cryptococcosis can be found in immunocompetent children, 11 it is more common in patients that have abnormality in cell-mediated immunity. 12 The patients in this study had normal T-cell counts and normal in vitro T-cell function, as tested by PHA stimulation. However, they may have recurrent fever and headache. Investigations revealed WBC 2,770 cells/mm 3 (neutrophils 35%, lymphocytes 56%, monocytes 8.8%). The ANC was 790 cells/mm 3 . The cryptococcal antigen titer was 1:256 in CSF, and > 1:1,024 in serum. Intravenous amphotericin B (1 mg/kg/day) and oral fluconazole (12 mg/kg/day) were restarted. During hospitalization, the ANC declined to 220 cells/mm 3 . He has received G-CSF twice a week since then. After 2 weeks of treatment, the cryptococcal antigen titer in CSF decreased to 1:64. Amphotericin B was discontinued, but oral fluconazole 12mg/kg/day was continued at the current dosage. During the subsequent 18-month follow-up, this patient had no recurrent cryptococcal infection while receiving this maintenance dose.
Two months after the onset of illness in patient A, his now 8-year-old cousin (patient B) developed fever with severe headache. Investigations revealed WBC 5,480 cells/mm 3 (neutrophils 11.7%, lymphocytes 66.4%, monocytes 13.5%). The ANC was 640 cells/mm 3 . CSF examination revealed WBC 280 cells/mm 3 , protein 59 mg/dl, and glucose 22 mg/dl. The cryptococcal antigen titer was > 1:1,024 in both CSF and serum. His CSF culture grew Cryptococcus neoformans. He received the same antifungal treatment prescribed for patient A, followed by maintenance oral fluconazole 12 mg/kg/day. Patient B had no recurrence of cryptococcal infection during the subsequent 16-month follow-up.
T-cell dysfunction that is specific to the cryptococcal antigen. In fact, not only T cell that plays role against host defense to cryptococcal infection, but also humoral and innate immune systems such as macrophages, dendritic cells, neutrophils, natural killer cells, eosinophils. 13 The role of antibody immunity protection against C. neoformans continues to be debated. The most probable action is opsonization for enhanced phagocytosis by macrophages.
14 Similar to our cases in this report, another study reported disseminated cryptococcal infection in a patient with hypogammaglobulinemia who had normal in vitro T-cell functions. 15 A previous study showed that patients who produced anticryptococcal antibodies in vivo had relatively better prognosis. 16 Furthermore, CD40 protein, the receptor of CD40L, is found on B cells, monocytes and dendritic cells. 17 Therefore, the defect in CD40L has an effect on the function of these innate immune cells. Taken together, these findings suggest a complex interplay of cellular, humoral, and innate immunity in host defense against cryptococcal infection.
Presence of neutropenia may predispose a patient to develop cryptococcosis. The mechanism of neutropenia is defect in myeloid cell development that is mediated by CD40-CD40L interaction.
18 Neutrophils kill C. neoformans primarily via NADPH oxidase-mediated ROS production, and through the release of neutrophil extracellular traps (NETs). 19 A previous study in C. neoformans-infected mice found that survival was increased after treatment with G-CSF. 20 The recommended antifungal treatment for disseminated cryptococcosis is amphotericin B plus flucytosine. However, fluconazole is more widely available and less expensive than flucytosine. In this study, both patients responded well to treatment, but breakthrough infection occurred with lower-dose fluconazole in patient A. Breakthrough infection occurred in 4% of adults with HIV/AIDS who were receiving fluconazole 200 mg/day (equivalent to 6 mg/kg/day in children), 21 and fluconazole at this dosage has been recommended as maintenance suppressive therapy. 22 Although there is no standard guideline for secondary cryptococcal prophylaxis in primary immunodeficiency patients, we decided to continue the suppressive therapy due to the severity of the disease. It remains unclear whether fluconazole resistance played a role in his relapse of cryptococcal infection despite prescribing the prophylaxis therapy. A recent systematic review of fluconazole resistance found that 24% of relapsed strain were resistant to fluconazole. 23 Therefore, we decided to increase the maintenance dose to 12 mg/kg/day to overcome the possibility of elevated minimum inhibitory concentration (MIC), and there has been no recurrent episode.
In conclusion, patients with XHIM are at increased risk of developing disseminated cryptococcal infection. In settings where flucytosine is not available or accessible, combination therapy consisting of amphotericin B and fluconazole yielded good outcomes. Low-dose fluconazole may not be sufficient to prevent recurrence.
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